The Etro Studies

Know the Past. Shape the Future.

Clinical Trial Endpoints

Some key objectives of the clinical trial program are:

Ulcerative Colitis:
Hibiscus I & II:

  • Induction of remission at Week 10 compared with placebo and compared with adalimumab

Hickory:

  • Induction of remission at Week 14 compared with placebo
  • Maintenance of remission for one year

Laurel:

  • Maintenance of remission for one year

Cottonwood:

  • Assessment of the long-term safety and efficacy of etrolizumab
  • PML safety monitoring

Ulcerative Colitis clinical trial programs available outside of the US are:
Gardenia:

  • Sustained remission compared with infliximab
  • Clinical response at Week 10
  • Sustained clinical response at Weeks 10, 30 and 54

Crohn’s Disease
Bergamot:

  • Induction of remission at Week 14 compared with placebo
  • Maintenance of remission for one year

Juniper:

  • Assessment of the long-term safety and efficacy of etrolizumab
  • PML safety monitoring

Read more about the Etro Studies

 

  • Print

Notice

×

The information contained in this section of the site is intended for U.S. healthcare professionals only. Please select OK if you are a U.S. healthcare professional.

Cancel OK